Prestige Consumer Healthcare (PBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Premium Brands Holdings Co. (TSE: PBH - Get Free Report) has been assigned an average recommendation of "Buy" from the ten brokerages that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to
Ariel Investments LLC lessened its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 12.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,202,327 shares of the company's stock after selling 316,614 shares during the quarter.
The consensus price target hints at a 26.1% upside potential for Prestige Consumer Healthcare (PBH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Fisher Asset Management LLC trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE: PBH) by 6.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 305,626 shares of the company's stock after selling 22,434 shares during the
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?
Premium Brands Holdings Corporation ( PBH:CA ) Q3 2025 Earnings Call November 10, 2025 1:30 PM EST Company Participants George Paleologou - President, CEO & Director Will Kalutycz - Chief Financial Officer Conference Call Participants Christopher Li - Desjardins Securities Inc., Research Division Martin Landry - Stifel Nicolaus Canada Inc., Research Division Kyle McPhee - Cormark Securities Inc., Research Division Derek Lessard - TD Cowen, Research Division Luke Hannan - Canaccord Genuity Corp., Research Division Michael Glen - Raymond James Ltd., Research Division Stephen MacLeod - BMO Capital Markets Equity Research Ty Collin - CIBC Capital Markets, Research Division Vishal Shreedhar - National Bank Financial, Inc., Research Division John Zamparo - Scotiabank Global Banking and Markets, Research Division Ryland Conrad - RBC Capital Markets, Research Division Presentation George Paleologou President, CEO & Director Good morning, and welcome, everyone, to our 2025 Third Quarter Conference Call.
Prestige Consumer Healthcare Inc. ( PBH ) Q2 2026 Earnings Call November 6, 2025 8:30 AM EST Company Participants Philip Terpolilli - Director of Investor Relations Ron Lombardi - Chairman, President & CEO Christine Sacco - CFO & COO Conference Call Participants Susan Anderson - Canaccord Genuity Corp., Research Division Rupesh Parikh - Oppenheimer & Co. Inc., Research Division Keith Devas - Jefferies LLC, Research Division Jon Andersen - William Blair & Company L.L.C., Research Division Mitchell Pinheiro - Sturdivant & Co., Inc., Research Division Anthony Lebiedzinski - Sidoti & Company, LLC Douglas Lane - Water Tower Research LLC Presentation Operator Good day, and thank you for standing by.
Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.07 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.09 per share a year ago.
